ClinicalTrials.gg
Status unknownNCT02579473Updated Apr 11, 2023

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

A Phase 1 interventional study of SER-214 in Parkinson's Disease, sponsored by Serina Therapeutics. Status unknown at 4 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by Serina Therapeutics · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
835th of 1,257
20 · median 36
Started
2016
with 72 others
Phase 1
175 of 1,650
32 open now
Registered
663rd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 835th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 73 that started in 2016, is one of 175 in phase 1, and was the 663rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

SER-214 is a poly (2-ethyl-2oxazoline)(POZ) polymer conjugate of rotigotine, a potent dopamine agonist that has high affinity for the subclass of dopamine receptors in the brain that mediate dopamine signaling. SER-214 will be administered subcutaneously once a week via a standard 1 mL insulin syringe to determine the safety, tolerability and pharmacokinetic (PK) profile of released rotigotine and POZ-conjugate. Subjects in this study are eligible if they have early, stable or untreated Parkinson's disease and are still experiencing motor fluctuations.

Read the detailed description

Clinical evidence suggests that dopamine agonists should be considered as an initial or early symptomatic therapy for PD. Current information indicates that the early use of long-acting dopaminergic agonists may protect against the development of motor complications by stimulating dopamine receptors in a non-pulsatile manner and by delaying the introduction of levodopa. In pre-clinical primate studies, L-dopa (short-acting, pulsatile) and dopaminergic agonists (long-acting; non pulsatile) provide comparable clinical benefit but with agonists inducing significantly less dyskinesia.

Chronic L-dopa treated animals develop gene changes that are associated with abnormal neuronal firing patterns and dyskinesias which are not seen with long-acting dopamine agonists. Based on pre-clinical and clinical study results, treatment of Parkinson's patients with long-acting levodopa or dopamine agonists should provide symptomatic benefit, and significantly delay the onset of motor complications. This can be accomplished with duodopa or continuous sc apomorphine but these treatments are associated with significant side effects. To date, no practical method of providing continuous drug delivery using a dopaminergic agent for therapy of patients with early PD to prevent the development of motor complications has been advanced through clinical trials.

SER-214 is being developed as a weekly sc injection that provides prompt onset of dopaminergic stimulation. Continuous levels of released rotigotine within the therapeutic window for relief of motor fluctuations have been observed in MPTP-treated cynomolgus macaques. PK determinations in normal monkeys for up to 13 weeks of treatment show that weekly injections of SER-214 provide continuous drug delivery of released plasma rotigotine within a predictable therapeutic range.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Continuous dopaminergic stimulation
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male subjects 40-80 years of age inclusive
  2. A diagnosis of idiopathic Parkinson's disease (PD) consistent with UK brain bank criteria
  3. De novo PD patients and those on a stable regimen of anti-Parkinson's drugs for at least 4weeks prior to screening including anticholingerics, amantadine, MAO-B inhibitors, COMT inhibitors or levodopa, but not dopamine agonists
  4. Free of motor complications as determined by the investigator
  5. Ability to complete up to four weeks of dosing once per week with two weeks of terminal "wash-out" PK
  6. Ability to return to the clinic for blood sampling, clinical and laboratory assessment on scheduled days, based upon cohort
  7. (MMSE) > 26
  8. Women of (WOCBP) must use a reliable method of (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive, double-barrier methods [such as condom plus diaphragm, condom plus spermicidal foam, condom plus sponge], or intra-uterine devices), and must have a negative serum pregnancy test at Screening and negative urine pregnancy test at baseline
  9. Willing and able to comply with the study requirements including follow-up
  10. Provide written
  11. Cognitively intact sufficient to understand and provide informed consent
  12. Approved by a central Eligibility Monitoring Committee (EMC) confirmed by EMC signature on the Enrollment Authorization Form (EAF)

Exclusion criteria

Exclusion Criteria:

  1. Subject has previously participated in this study.
  2. Myocardial infarction within the past six months from screening
  3. Ischemic stroke or transient ischemic event within the past two years from screening
  4. Known sensitivity to dopamine agonists including nausea/vomiting, orthostatic hypotension, excessive sleep or impulse control disorder
  5. Any major organ disease that substantially impairs
  6. History of cancer, other than basal cell carcinoma, within the past 10 years or subjects with any laboratory or physical exam or diagnostic procedure finding suggestive of current
  7. Subjects who are known to be or are receiving chronic treatment with immunosuppressive drugs
  8. Subject with an atypical or secondary Parkinsonian (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease)
  9. Any medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
  10. Subject has moderate renal impairment (creatine > 2.5)
  11. Subject has moderate ( categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.
  12. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (CSSRS) at Screening
  13. Subject has known to rotigotine or to any components or of the study drug
  14. Subject has a history of psychosis or hallucinations within the previous 12 months
  15. Subject has received an drug within 30 days of screening or is currently participating in an investigational drug or investigational device trial
  16. Subject, who, for any reason, is judged by the Investigator to be inappropriate for this study, including a subject who is unable to communicate or cooperate with the Investigator or who has/had a clinically significant illness or abnormal physical examination that may compromise safety of the subject during the trial or affect ability of the subject to adhere to study procedures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cohort 0

    Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal "wash-out" of rotigotine and pro-drug SER-214.

    Drug: SER-214

  • Experimental
    Cohort 1

    Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal "wash-out" of rotigotine and pro-drug SER-214.

    Drug: SER-214

  • Experimental
    Cohort 2

    Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal "wash-out" of rotigotine and pro-drug SER-214.

    Drug: SER-214

  • Experimental
    Cohort 3

    Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal "wash-out" PK of rotigotine and pro-drug SER-214.

    Drug: SER-214

Interventions

  • DrugSER-214

    SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection

    Also known as: POZ-rotigotine

06

What researchers measure

Primary outcomes

  1. Safety - Adverse Events and Serious Adverse Events

    Change from Screening in frequency of adverse events (AEs) and serious adverse events (SAEs) at the Final Safety Visit

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

  2. Percentage of patients in each cohort who discontinued therapy due to any adverse events {Tolerability}

    Percentage of patients in each cohort who discontinued therapy due to any adverse events will be used as an assessment of tolerability

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

  3. Safety - Vital Signs

    Change from Screening in assessment of vital signs (pulse, blood pressure) at each study visit and Final Safety Visit

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

  4. Safety - Abnormal Laboratory Results

    Change from Screening in number of participants with laboratory test values of potential clinical importance

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

  5. Safety - Treatment-Emergent Adverse Events

    Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to \[study drug\] will be assessed by the investigator (Yes/No).

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

  6. Safety - ECG Changes

    Change from Screening in assessment of electrocardiogram (ECG) parameters at each injection visit

    Time frame: From initial sc dose of SER-214 up to six weeks of follow-up

Secondary outcomes

  1. Fluctuation index

    On injection days plasma samples will be taken at time 0 (baseline), 1, 2, 4 and 8 hours post injection. PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the Fluctuation Index

    Time frame: On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours

  2. Maximum plasma concentration [C(max)]

    PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the C(max)

    Time frame: On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours

  3. Time to maximum concentration [T(max)]

    PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the T(max)

    Time frame: On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours

  4. Dose-adjusted area under the curve (AUC)

    PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the dose-adjusted AUC

    Time frame: On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours

  5. Unified Parkinson's Disease Rating Scale

    The UPDRS total (Parts I, II and III) will be determined at each study site visit and the Final Safety Visit

    Time frame: From Screening up to six weeks of follow-up

  6. Unified Parkinson's Disease Rating Scale - Motor Part III Only

    The Motor UPDRS (Part III) will be determined as a separate outcome measure at each injection day visit

    Time frame: From Screening up to six weeks of follow-up

  7. Epworth Sleepiness Scale (ESS)

    The ESS will be determined at Screening, first Follow-up visit, Final Safety Visit and any unscheduled visit to determine if escalating doses of SER-214 are associated with increase in somnolence

    Time frame: From Screening up to six weeks of follow-up

  8. Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS will be determined at Screening and Final Safety Visit and any unscheduled visit. C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior").

    Time frame: From Screening up to six weeks of follow-up

  9. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP)

    The QUIP will be assessed at Screening and on the Final Safety Visit and any unscheduled visit to determine if there is any association between Impulsive-Compulsive behavior and SER-214 dose

    Time frame: From screening up to six weeks of follow-up

07

Study locations

4 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
08

References and documents

Publications

  • Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3. PubMed 24014074 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2016 (actual). Primary completion is estimated for Dec 2023, 95 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 95 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Oct 19, 2015
StartActual
Jan 2016
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02579473
Lead sponsor
Serina Therapeutics
Responsible party
Sponsor
First posted
Oct 19, 2015
Start date
Jan 2016
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Apr 11, 2023

Study contacts

David G Standaert, MD, PhD
principal investigator · Univeristy of Alabama-Birmingham School of Medicine, Division of Neurology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion